The A-List: 2004's Trend-Shaping Series A Financings

Analyzing the venture financings closed by 2004's new crop of biotech, diagnostics, and medical device start-ups reveals today's trends that may shape tomorrow's health care industry. Here we point out eleven 2004 Series A financings that identify and illustrate what's hot.

The return of the health care IPO market in late 2003 certainly buoyed industry spirits, particularly in venture capital and entrepreneurial sectors, although VCs on the whole could be forgiven for not being ecstatic about the valuations their portfolio companies were grabbing. Initial public offerings continued throughout 2004, and while few companies of any stripe were able to pair outstanding valuations with solid post-float performances, as we have pointed out throughout the duration of the window in our Valuation Watch columns, in the end it mattered little to the overall scheme. Public money was returning to younger biotech and medical device firms in levels not seen in a few years. (See, for example, "IPO Step-Ups By Therapeutic Area: Is Your Disease Focus Hot or Not?" START-UP, December 2004 Also see "IPO Step-Ups By Therapeutic Area: Is Your Disease Focus Hot or Not?" - Scrip, 1 December, 2004..)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By 

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Biotech Leaders Ponder Tariff Ramifications

 

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By 

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By 

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By 

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.